More patients are now surviving cancer thanks to early diagnosis and improved treatment. Chronic pain in cancer survivors is problematic and the risk of chronic therapy with opioids includes abuse or addiction. We describe a patient with lymphoma whose behavior became aberrant while under treatment with opioid analgesics to manage anxiety after a painful tumor disappeared. Using opioid analgesics to manage emotional distress rather than pure physical pain has been defined as chemical coping, which is considered as an early stage of abuse or addiction. Knowledge of opioid analgesics and aberrant drug-related behaviors is necessary to manage chronic pain in cancer survivors.

Tumor lysis syndrome (TLS) is an oncological emergency characterized by various metabolic abnormalities, such as hyperuricemia, hyperphosphatemia, hyperkalemia and hypocalcemia. Although TLS is rare in solid tumors, it has been reported in various cancers and sarcomas. It can be caused by chemotherapy, radiotherapy, surgical procedures. TLS in solid tumors may be lethal when it once develops. Hence, prophylaxis is considered important in medium risk diseases. We experienced the case that serum lactate dehydrogenase (LDH) level had elevated drastically a month prior to the onset of TLS in hypopharyngeal cancer. It is suggested that monitoring of LDH may be helpful for predicting the onset of TLS.

In Kyoto, we held the first “Palliative care workshop for physicians engaged in clinical practice for cancer treatment” in Japan on June 7-8, 2008 under the directive of the Ministry of Health, Labor and Welfare. There were 163 participants in the workshop, including 56 physicians and 107 voluntarily participating healthcare professionals (77 nurses, 23 pharmacists and 7 other medical professionals). We analyzed the results of tests consisting of 25 questions classified into 7 categories based on their contents. Tests were administered before and after the workshop (pre-test and post-test), and the educational effects of our conference were evaluated by examining changes in test scores. Participants other than physicians, nurses and pharmacists were excluded from analysis of the test scores because comprehensive medical knowledge was required to solve the questions. The mean rates of correct answers on pre- and post-test were 87.9% for physicians (total 78.9%) and 94.6% for physicians (total 89.1%), respectively. The scores were markedly increased after the workshop, showing practical significance of our attempt. However, the percentage of correct answers regarding psychological symptoms was lowest for physicians as well as for other healthcare professionals on both pre- and post-test. These findings strongly suggest that the workshops produced a sufficient educational effect, but improvement in individual training systems is considered necessary, especially in fields related to psychological manifestations. Palliat Care Res 2010; 5(2): 152-161

The aim of this study was to clarify the prevalence and characteristics of breakthrough pain in cancer patients. We conducted a cross-sectional survey of consecutive patients older than 20 years of age admitted to a University Hospital with a cancer diagnosis Breakthrough pain was defined as meeting all of the following criteria： Pain 1）with background pain present most of the time, 2）which is well controlled, 3）with short-lived episodes of exacerbation. One hundred and sixty-nine patients were recruited and 118（69.8％）completed the survey. Of these 118 patients, 11％（95％CI：7–18％）had breakthrough pain. Breakthrough pain occurred in 23％（14–35％）of patients with cancer-related pain and 29％（17–45％）of patients with pain from the cancer itself. Patients reported episodes occurring up to three times a day,a time to peak intensity of within 5 minutes, and a duration of untreated episodes of up to 15 minutes are 54％（29–77％）, 54％（29–77％）, 54％（29–77％）, respectively.

This study aimed to estimate the cost-effectiveness of pregabalin treatment for neuropathic pain.
Design:Long-term simulations based on state transition models.
Methods:We examined the cost-effectiveness of pregabalin for treatment of three common peripheral neuropathic pains, postherpetic neuralgia(PHN), painful diabetic peripheral neuropathy(DPN), and radiculopathy, using the incremental cost-effectiveness ratio(ICER). We used quality-adjusted life years(QALYs)as an index of effectiveness, and also estimated medical costs. For PHN and DPN, we constructed state transition models comprising two states, with and without pregabalin treatment, and performed 52-week simulations. The pain scores reported in Japanese phaseIII studies were used to set patients' weekly pain scores. The results of utility surveys conducted overseas were used as utility scores, while values randomly sampled from probability distributions were used to set weekly pain scores and drop-out rates. In base-case analyses, we performed 1000 1st-order Monte Carlo simulations using 1000 values randomly sampled from probability distributions, and calculated QALYs and medical costs for 52 weeks for each group. For radiculopathy, the ICER was calculated from changes in QALYs for 12 weeks reported overseas and medical costs estimated separately for the identical period.
Results:The ICERs for PHN, DPN, and radiculopathy were 1,116,886 Yen/QALY, 1,100,420 Yen/QALY, and 1,095,943 Yen/QALY, respectively, which were well below the upper limits of ICER ranges for treatments considered cost-effective. There were no cases in which ICERs obtained from scenario and sensitivity analyses differed significantly.
Conclusion:Pregabalin was shown to be cost-effective treatment for neuropathic pain.

Headaches caused by metastatic brain tumors result from dural tension and traction of the sites of nociceptive nerves that originates from displacement of cerebral vessels and intracranial hypertension caused by the tumor. Causes of such headaches also include meningeal irritation resulting from intrathecal dissemination of tumor and carcinomatous meningitis.Treatment of headaches resulting from intracranial hypertension involves alleviation of cerebral edema and reduction of intracranial pressure using hyperosmolar therapy and steroid administration, but treatment is often complicated by a lack of pressure reduction. We encountered 2 cases of headaches with intracranial hypertension that did not improve following hyperosmolar therapy and steroid administration, but resolved with increased opioid dose.In cases where intracranial pressure does not decrease, or for headaches attributed to direct stimulus of intracranial nociceptive nerves rather than intracranial hypertension, attempts to treat the patient with initiation or increased dosage of opioids may prove effective from a clinical standpoint.

Purpose: The field survey was conducted to evince the current status of palliative care for non-cancer patients. Methods: The on-line questionnaire survey was conducted covering 196 representatives of the Japanese Society for Palliative Medicine. Multiple-choice questions were asked about their medical experiences with non-cancerous diseases, their attitudes towards palliative care, their feelings of bewilderment upon providing palliative care, and what they thought would be required for future education in this field. Results: One-hundred and eleven (111) representatives (57%) responded the survey. Ninety-nine (99)% of the respondents experienced providing non-cancer patients with palliative care, but 63% of them experienced less than 50 patients in the terminal phases even in cumulative total. Eighty (80)% of them said they were feeling insecure about providing non-cancer patients with palliative care, and 83% of them were feeling difficulty when they had to do so. The reasons listed included that prognostic prediction for such cases wouldn’t be easy and that it wouldn’t be covered by public health insurances. What they felt necessary about future education included communication and multi-disciplinary team medicine, in this order. Conclusions: The representatives of the Japanese Society for Palliative Medicine are well-aware of the demands for palliative care for non-cancer patients, but not many of them have experienced such cases and more than 80% of them are feeling insecure and difficulty about providing it.